Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
377
datasets available to search
ShareScore release 0.9.0
Dataset results
377 results for “GLP-1”
GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis
ClinicalTrials.gov study NCT07251556. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Investigation of the Evolution of Gastric Emptying by Gastric Ultra Sonography in Patients Treated With GLP-1 Receptor Agonists on a 7 Days Pausing Period.
ClinicalTrials.gov study NCT06388213. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT00655603. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Gastric Emptying in Healthy Volunteers and GLP-1 Agonist Users
ClinicalTrials.gov study NCT06987669. IPD Sharing: Not stated. Countries: 0. Publications: 0.
GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients
ClinicalTrials.gov study NCT01592279. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, glucose production and its absence alters liver disease progression (F480+ CELLS)
GEO Series GSE218766. Mus musculus. 31 samples. Type: Expression profiling by array.
Expression data from glp-1(e2141) hermaphrodites maintained with or without males for 8 days
GEO Series GSE51691. Caenorhabditis elegans. 11 samples. Type: Expression profiling by array.
Targeting GLP-1 signaling ameliorates cystogenesis in a zebrafish model of nephronophthisis
GEO Series GSE291847. Danio rerio. 6 samples. Type: Expression profiling by high throughput sequencing.
GLP-1 induced transcriptomic profile in INS-1 cells
GEO Series GSE102003. Rattus norvegicus. 24 samples. Type: Expression profiling by high throughput sequencing.
Behavioural and neurochemical mechanisms underpinning the synergistic feeding-suppressive effect of GLP-1/CCK combinatorial therapy
GEO Series GSE135862. Mus musculus. 48 samples. Type: Expression profiling by high throughput sequencing.
Fig. 1 in Norlignans as potent GLP-1 secretagogues from the fruits of Amomum villosum
Fig. 1. Structures of compounds 1–4.
Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl Syndrome mouse model
GEO Series GSE293590. Mus musculus. 10 samples. Type: Expression profiling by high throughput sequencing.
GLP-1 signaling suppresses menin's transcriptional block by phosphorylation in beta cells
GEO Series GSE106653. Rattus norvegicus. 6 samples. Type: Expression profiling by high throughput sequencing.
Next Generation Sequencing for Transcriptomes Analysis in GLP-1 Notch receptor ON and OFF genetic background
GEO Series GSE144229. Caenorhabditis elegans. 10 samples. Type: Expression profiling by high throughput sequencing.
Bioengineering the metabolic network of CAR T-cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity
Open the record for dataset details and reuse information.
A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: Further link between metabolism and psychopathology
<p>Raw data. Contains outcome and treatment data for selected publications that were analyzed i nthe study. File in ready to use for meta-analysis.</p>
Dataset related to article: "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study"
<p>This record contains data related to article "<strong>Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study" </strong></p><p>Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in cardiovascular outcome trials in type 2 diabetes mellitus. However, the most convincing evidence was obtained in subjects with established cardiovascular (CV) disease. We analyzed the determinants of GLP-1 RA-mediated CV protection in a real-world population of persons with type 2 diabetes with and without a history of CV events with long-term follow-up.</p><p>Methods: Retrospective cohort study of 550 individuals with type 2 diabetes (395 in primary CV prevention, 155 in secondary CV prevention), followed at a single center after the first prescription of a GLP-1 RA between 2009 and 2019. CV and metabolic outcomes were assessed.</p><p>Results: Median duration of follow-up was 5.0 years (0.25-10.8) in primary prevention and 3.6 years (0-10.3) in secondary prevention, with a median duration of treatment of 3.2 years (0-10.8) and 2.5 years (0-10.3) respectively. In the multivariable Cox regression model considering GLP-1 RA treatment as a time-dependent covariate, in the primary prevention group, changes in BMI and glycated hemoglobin did not have an impact on MACE risk, while age at the time of GLP-1 initiation (HR 1.08, 95% CI 1.03-1.14, p = 0.001) and GLP-1 RA cessation by time (HR 3.40, 95% CI 1.82-6.32, p < 0.001) increased the risk of MACE. Regarding the secondary prevention group, only GLP-1 RA cessation by time (HR 2.71, 95% CI 1.46-5.01, p = 0.002) increased the risk of MACE. With respect to those who withdrew treatment, subjects who continued the GLP-1 RA had significantly greater weight loss and lower glycated hemoglobin levels during follow-up.</p><p>Conclusions: In this real-world type 2 diabetes population, discontinuation of GLP-1 RA treatment was associated to a higher risk of major cardiovascular events, in both subjects with and without a history of CV events.</p><p> </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.